SpaceFOMO
SpaceFOMO
Feed
Contract Live / BioOrbit

BioOrbit receives £250,000 UK Space Agency feasibility study

The UK Space Agency provided funding for a £250,000 feasibility study to develop a scalable in-orbit manufacturing system for crystallising biologic drugs used in cancer treatment. The study, funded through the Unlocking Space Portfolio, involves BioOrbit, the MHRA, and the UK Space Agency. It runs until March 2026 and is intended to clarify whether existing terrestrial pharmaceutical regulations apply to in-orbit manufacturing for patient use.

Why it matters

The study addresses a central commercial barrier for space pharmaceutical manufacturing: regulatory clarity. A favourable outcome would give BioOrbit a stronger path from demonstration experiments to patient-facing products.

The numbers

Contract
£250K

including a £250,000 feasibility study for BioOrbit

Source

Coverage

1 report
  1. ADS Group ·

    Collaboration to support in-orbit pharmaceuticals manufacturing

    The UK Space Agency awarded BioOrbit a £250,000 feasibility study under its Unlocking Space Portfolio to define the regulatory pathway for manufacturing pharmaceuticals in orbit. BioOrbit, the MHRA, and the UK Space Agency will assess whether existing terrestrial pharmaceutical regulations apply to in-orbit production for patient use.

    56

AI-assisted summary of 1 report; numbers link to their source. Spot an error? Tell us.

More from BioOrbit

Full BioOrbit timeline →

Related moments

Veenie.Space Telemetry

Simulate BioOrbit hardware

The UK Space Agency provided funding for a £250,000 feasibility study to develop a scalable in-orbit

Get launch moments in your inbox

A weekly digest of the moments you'd regret missing. Starting soon: get on the list.